Key Takeaways
- Nuevocor appoints Dr. Thierry Abribat to its Board to enhance its clinical development in cardiomyopathies.
- Dr. Abribat has a notable history in biotech, including the $1 billion acquisition of Amolyt Pharma by AstraZeneca.
- Nuevocor plans to initiate a Phase 1/2 clinical trial for its gene therapy NVC-001 in early 2026.
New Board Member to Accelerate Nuevocor’s Growth
Nuevocor, a biotechnology company based in Singapore, has appointed Dr. Thierry Abribat to its Board of Directors. This strategic move aims to bolster the company’s advancement toward becoming a clinical-stage entity focused on innovative therapies for genetic cardiomyopathies caused by aberrant mechanobiology.
Dr. Abribat brings extensive experience as a biotech executive and serial entrepreneur, having founded and led three successful biotechnology firms. His recent achievement includes orchestrating the $1 billion acquisition of Amolyt Pharma by AstraZeneca, highlighting his expertise in scaling biotech companies for lucrative exits. Previously, he was involved with Alizé Pharma and Alizé Pharma 2, both of which were acquired by larger pharmaceutical companies. His leadership roles encompass positions as Chief Scientific Officer at Theratechnologies and Chief Operating Officer at OPi SA, a company focused on rare diseases.
Expressing his enthusiasm, Dr. Abribat stated, “I am excited to join Nuevocor at such a pivotal time in its journey toward becoming a clinical-stage company.” He emphasized the transformative potential of Nuevocor’s mechanobiology approach for patients dealing with genetic cardiomyopathies. Dr. Andreas Wallnöfer, Chairman of the Board, acknowledged Dr. Abribat’s achievements, noting that his strategic insights and leadership will be invaluable as Nuevocor expands its presence in Europe and advances its objectives.
Nuevocor is developing NVC-001, a first-in-class AAV-based gene therapy targeting LMNA-related dilated cardiomyopathy (LMNA DCM), a severe form of heart disease. The therapy aims to restore nuclear envelope integrity, a critical aspect affected in LMNA DCM. Preliminary studies have shown significant advantages in cardiac function and patient survival. The company plans to launch a Phase 1/2 clinical trial for NVC-001 in early 2026 across sites in the U.S. and Europe.
With its innovative approach and the addition of Dr. Abribat, Nuevocor is positioned to address significant gaps in treatment options for genetic cardiomyopathies, representing a promising avenue for future therapies.
The content above is a summary. For more details, see the source article.
